Socioeconomic inequalities in cancer mortality between and within countries in Europe: a population-based study.
Between- and within countries cancer inequalities
Cancer disparities
Cancer mortality
Social gradient
Socioeconomic inequalities
Journal
The Lancet regional health. Europe
ISSN: 2666-7762
Titre abrégé: Lancet Reg Health Eur
Pays: England
ID NLM: 101777707
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
16
05
2022
revised:
03
11
2022
accepted:
08
11
2022
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
24
2
2023
Statut:
epublish
Résumé
Reducing socioeconomic inequalities in cancer is a priority for the public health agenda. A systematic assessment and benchmarking of socioeconomic inequalities in cancer across many countries and over time in Europe is not yet available. Census-linked, whole-of-population cancer-specific mortality data by socioeconomic position, as measured by education level, and sex were collected, harmonized, analysed, and compared across 18 countries during 1990-2015, in adults aged 40-79. We computed absolute and relative educational inequalities; temporal trends using estimated-annual-percentage-changes; the share of cancer mortality linked to educational inequalities. Everywhere in Europe, lower-educated individuals have higher mortality rates for nearly all cancer-types relative to their more highly-educated counterparts, particularly for tobacco/infection-related cancers [relative risk of lung cancer mortality for lower- versus higher-educated = 2.4 (95% confidence intervals: 2.1-2.8) among men; = 1.8 (95% confidence intervals: 1.5-2.1) among women]. However, the magnitude of inequalities varies greatly by country and over time, predominantly due to differences in cancer mortality among lower-educated groups, as for many cancer-types higher-educated have more similar (and lower) rates, irrespective of the country. Inequalities were generally greater in Baltic/Central/East-Europe and smaller in South-Europe, although among women large and rising inequalities were found in North-Europe (relative risk of all cancer mortality for lower- versus higher-educated ≥1.4 in Denmark, Norway, Sweden, Finland and the England/Wales). Among men, rate differences (per 100,000 person-years) in total-cancer mortality for lower-vs-higher-educated groups ranged from 110 (Sweden) to 559 (Czech Republic); among women from approximately null (Slovenia, Italy, Spain) to 176 (Denmark). Lung cancer was the largest contributor to inequalities in total-cancer mortality (between-country range: men, 29-61%; women, 10-56%). 32% of cancer deaths in men and 16% in women (but up to 46% and 24%, respectively in Baltic/Central/East-Europe) were associated with educational inequalities. Cancer mortality in Europe is largely driven by levels and trends of cancer mortality rates in lower-education groups. Even Nordic-countries, with a long-established tradition of equitable welfare and social justice policies, witness increases in cancer inequalities among women. These results call for a systematic measurement, monitoring and action upon the remarkable socioeconomic inequalities in cancer existing in Europe. This study was done as part of the LIFEPATH project, which has received financial support from the European Commission (Horizon 2020 grant number 633666), and the DEMETRIQ project, which received support from the European Commission (grant numbers FP7-CP-FP and 278511). SV and WN were supported by the French Institut National du Cancer (INCa) (Grant number 2018-116). PM was supported by the Academy of Finland (#308247, # 345219) and the European Research Council under the European Union's Horizon 2020 research and innovation programme (grant agreement No 101019329). The work by Mall Leinsalu was supported by the Estonian Research Council (grant PRG722).
Sections du résumé
Background
UNASSIGNED
Reducing socioeconomic inequalities in cancer is a priority for the public health agenda. A systematic assessment and benchmarking of socioeconomic inequalities in cancer across many countries and over time in Europe is not yet available.
Methods
UNASSIGNED
Census-linked, whole-of-population cancer-specific mortality data by socioeconomic position, as measured by education level, and sex were collected, harmonized, analysed, and compared across 18 countries during 1990-2015, in adults aged 40-79. We computed absolute and relative educational inequalities; temporal trends using estimated-annual-percentage-changes; the share of cancer mortality linked to educational inequalities.
Findings
UNASSIGNED
Everywhere in Europe, lower-educated individuals have higher mortality rates for nearly all cancer-types relative to their more highly-educated counterparts, particularly for tobacco/infection-related cancers [relative risk of lung cancer mortality for lower- versus higher-educated = 2.4 (95% confidence intervals: 2.1-2.8) among men; = 1.8 (95% confidence intervals: 1.5-2.1) among women]. However, the magnitude of inequalities varies greatly by country and over time, predominantly due to differences in cancer mortality among lower-educated groups, as for many cancer-types higher-educated have more similar (and lower) rates, irrespective of the country. Inequalities were generally greater in Baltic/Central/East-Europe and smaller in South-Europe, although among women large and rising inequalities were found in North-Europe (relative risk of all cancer mortality for lower- versus higher-educated ≥1.4 in Denmark, Norway, Sweden, Finland and the England/Wales). Among men, rate differences (per 100,000 person-years) in total-cancer mortality for lower-vs-higher-educated groups ranged from 110 (Sweden) to 559 (Czech Republic); among women from approximately null (Slovenia, Italy, Spain) to 176 (Denmark). Lung cancer was the largest contributor to inequalities in total-cancer mortality (between-country range: men, 29-61%; women, 10-56%). 32% of cancer deaths in men and 16% in women (but up to 46% and 24%, respectively in Baltic/Central/East-Europe) were associated with educational inequalities.
Interpretation
UNASSIGNED
Cancer mortality in Europe is largely driven by levels and trends of cancer mortality rates in lower-education groups. Even Nordic-countries, with a long-established tradition of equitable welfare and social justice policies, witness increases in cancer inequalities among women. These results call for a systematic measurement, monitoring and action upon the remarkable socioeconomic inequalities in cancer existing in Europe.
Funding
UNASSIGNED
This study was done as part of the LIFEPATH project, which has received financial support from the European Commission (Horizon 2020 grant number 633666), and the DEMETRIQ project, which received support from the European Commission (grant numbers FP7-CP-FP and 278511). SV and WN were supported by the French Institut National du Cancer (INCa) (Grant number 2018-116). PM was supported by the Academy of Finland (#308247, # 345219) and the European Research Council under the European Union's Horizon 2020 research and innovation programme (grant agreement No 101019329). The work by Mall Leinsalu was supported by the Estonian Research Council (grant PRG722).
Identifiants
pubmed: 36818237
doi: 10.1016/j.lanepe.2022.100551
pii: S2666-7762(22)00247-2
pmc: PMC9929598
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100551Subventions
Organisme : Medical Research Council
ID : MR/S019669/1
Pays : United Kingdom
Informations de copyright
© 2022 Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
We declare no competing interests.
Références
Lancet Oncol. 2016 Oct;17(10):1445-1452
pubmed: 27567054
Int J Equity Health. 2019 Dec 3;18(1):189
pubmed: 31796079
Radiol Oncol. 2020 Feb 19;54(1):1-13
pubmed: 32074075
Lancet Gastroenterol Hepatol. 2019 Jul;4(7):511-518
pubmed: 31105047
EClinicalMedicine. 2020 Feb 04;19:100261
pubmed: 32055791
Br J Cancer. 2010 Aug 10;103(4):446-53
pubmed: 20588275
Lancet. 2020 Jul 4;396(10243):11-13
pubmed: 32622382
BMJ Open. 2021 Dec 23;11(12):e052646
pubmed: 34949618
Epidemiol Rev. 1986;8:1-27
pubmed: 3533579
Eur J Public Health. 2017 Oct 1;27(suppl_4):14-17
pubmed: 29028239
Popul Health Metr. 2021 Jan 30;19(1):3
pubmed: 33516235
Nicotine Tob Res. 2017 Nov 07;19(12):1401-1407
pubmed: 27679607
BMJ Open. 2016 Apr 05;6(4):e008985
pubmed: 27048630
Int J Equity Health. 2021 Sep 24;20(1):211
pubmed: 34560888
Lancet. 2017 Feb 25;389(10071):847-860
pubmed: 27814965
Eur J Cancer Prev. 2022 Sep 1;31(5):473-481
pubmed: 35044985
Br J Cancer. 2022 Jun;126(10):1490-1498
pubmed: 35149855
Eur J Epidemiol. 2019 Dec;34(12):1131-1142
pubmed: 31729683
Int J Epidemiol. 2007 Feb;36(1):66-76
pubmed: 17227779
IARC Monogr Eval Carcinog Risks Hum. 2010;96:3-1383
pubmed: 21735939
Int J Epidemiol. 2001 Apr;30(2):268-74
pubmed: 11369726
Eur J Public Health. 2014 Jun;24(3):370-7
pubmed: 24568755
Lancet. 2017 Mar 25;389(10075):1229-1237
pubmed: 28159391
CA Cancer J Clin. 2018 Sep;68(5):324-326
pubmed: 30152865
Lancet Oncol. 2021 Nov;22(11):1632-1642
pubmed: 34653370
J Health Soc Behav. 1995;Spec No:80-94
pubmed: 7560851
Br J Dermatol. 2020 May;182(5):1136-1147
pubmed: 31529485
Eur J Cancer. 2013 Oct;49(15):3262-73
pubmed: 23751569
Gastroenterol Clin North Am. 2013 Jun;42(2):219-40
pubmed: 23639638
BMC Cancer. 2017 Jul 5;17(1):470
pubmed: 28679369
Eur J Public Health. 2013 Apr;23(2):332-9
pubmed: 22562712
Front Public Health. 2020 May 12;8:118
pubmed: 32478023
Cancer. 2021 Aug 15;127(16):3029-3030
pubmed: 34086348
PLoS One. 2012;7(7):e39013
pubmed: 22848347
Int J Cancer. 2015 Mar 1;136(5):1125-39
pubmed: 24996155
Br J Cancer. 2008 Mar 11;98(5):1012-9
pubmed: 18283307